Insulin receptors and insulin action

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 5, 1996, Pages 369-377

  De Meyts, Pierre ^a   Christoffersen, Claus T ^a   Tornqvist, Hans ^a   Seedorf, Klaus ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001890650     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. McDonald NQ, Murray-Rust J, Blundell TL: The first structure of a receptor tyrosine kinase domain: a further step in understanding the molecular basis of insulin action. Structure 1995, 3:1-6.
2. De Meyts P, Ursø B, Christoffersen CT, Shymko RM: Mechanism of Insulin and IQF-1 receptor activation and signal transduction specificity. Receptor dimer cross-linking, bell-shaped curves, and sustained versus transient signaling. Ann N Y Acad Sci 1995, 766:388-401.
3. Myers MG Jr, White MF: Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol 1996, 36:615-658. The most current, up-to-date, comprehensive, and insightful review of the insulin signal transduction pathways, with 234 references. Many of the primary refer ences that we were not able to quote here for lack of space will be found in this review.
4. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers MG Jr, Glasheen E, Lane WS, Pierce JH, White MF: Role of IRS-2 in insulin and cytokine signalling. Nature 1995, 377:173-177. The cloning from myeloid progenitor cells of the second characterized member of the IRS family; whether there are more is one of the hot questions in the field.
5. Patti ME, Sun XJ, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1 deficient mice. J Biol Chem 1995, 270:24670-24673. IRS-1 knockout mice caused a surprise by showing only mild insulin resistance rather than diabetes. The demonstration of compensation by IRS-2 was the first evidence of redundancy or compensation among insulin signaling pathways.
6. Tobe K, Tamemoto H, Yamauchi T, Aizawa S, Yazaki Y, Kadowaki T: Identification of a novel substrate for the insulin receptor kinase functionally similar to insulin receptor substrate-1. J Biol Chem 1995, 270:5698-5701. IRS-1 knockout mice caused a surprise by showing only mild insulin resistance rather than diabetes. The demonstration of compensation by IRS-2 was the first evidence of redundancy or compensation among insulin signaling pathways.
7. Holgado-Madruga M, Emlet DR, Moscatello Dk, Godwin AK, Wong AJ: A Grb2-associated docking protein in EGF- and insulin receptor signalling. Nature 1996, 379:560-564.
8. Lemmon MA, Ferguson KM, Schlessinger J: PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell 1996, 85:621-624.
9. Ferguson KM, Lemmon M, Schlessinger J, Sigler PB: Structure of the high affinity complex of inositol triphosphate with a PLC pleckstrin homology domain. Cell 1995, 83:1037-1046.
10. Hyvonen M, Macias MJ, Nilges M, Oshkinat H, Saraste M, Wilmanns M: Structure of the binding sites for inositol phosphates in a PH domain. EMBO J 1995, 14:4676-4685.
11. Eck MJ, Dhe-Paganon SD, Trüb T, Nolte R, Shoelson SE: Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell 1996, 85:695-705. An essential structure linking the insulin receptor to downstream signaling has been identified (not to mention another tiny piece of the receptor).
12. Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E: Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino-acids 591-786. J Biol Chem 1996, 271:5980-5983. An interesting study that suggests a different binding mode to the insulin receptor for IRS-1 and IRS-2.
13. Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci P: Not all Shc's roads lead to Ras. Trends Biochem Sci 1996, 21:257-261.
14. Paz K, Voliovitch H, Hadari YR, Roberts CT, LeRoith D, Zick Y: Interaction between the Insulin receptor and Its downstream effectors. J Biol Chem 1996, 271:6998-7003.
15. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995, 9:726-735. An up-to-date review of an essential growth factor signaling pathway whose importance for insulin metabolic effects is now in question.
16. Seedorf K: Intracellular signaling by growth factors. Metabolism 1995, 44(suppl 4):24-32.
17. Maignan S, Guilloteau J-P, Fromage N, Amoux B, Becquart J, Ducruix A: Crystal structure of the mammalian Grb2 adaptor. Science 1995, 268:291-293.
18. Pruett W, Yuan Y, Rose E, Batzer AG, Harada N, Skolnick EY: Association between GrbZ/Sos and Insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interleukin-4: implications for Ras activation by insulin. Mol Cell Biol 1995, 15:1778-1785.
19. Ravichandran K, Lorenz U, Shoelson S, Burakoff S: Interaction of Shc with Grb2 regulates association of Grb2 with mSOS. Mol Cell Biol 1995, 15:593-600.
20. de Vries-Smits AMM, Pronk GJ, Medema JP, Burgering BMT, Bos JL: Shc associates with an unphosphorylated form of the p21 ras guanine nucleotide exchange factor mSOS. Oncogene 1995, 10:919-925.
21. Cherniack AO, Klarlund JK, Conway BR, Czech M: Disassembly of Son-of-sevenless proteins from Grb2 during p21 ras desensitization by insulin. J Biol Chem 1995, 270:1485-1488. One important demonstration that the kinetics of interaction of signaling molecules are an important aspect of signal regulation.
22. Waters SB, Holt KH, Ross SE, Syu L-J, Guan K-L, Saltiel AR, Koretzky GA, Pessin JE: Desensitization of Ras activation by a feedback disassociation of the SOS-Grb2 complex. J Biol Chem 1995, 270:20883-20886. One demonstration that the kinetics of interaction of signaling molecules is an important aspect of signal regulation.
23. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM: Negative feedback regulation and desensitization of insulin-stimulated and epidermal growth factor stimulated p21 ras activation. J Biol Chem 1995, 270:25320-25323. One demonstration that the kinetics of interaction of signaling molecules is an important aspect of signal regulation.
24. Miyaji I, Niederfellner G, White MF: IRS-1 and IRS-2 interact with a new member of the peptidyl-prolyl cis/trans isomerase (PPiase) family. Diabetes 1996, 45(suppl 2):438.
25. Algenstadt P, Antonetti DA, Kahn CR: Novel interactions of IRS-1 in human skeletal muscle. Exp Clin Endocrinol Diabetes 1996, 104(suppl 2):145-146.
26. Platanias LC, Uddin S, Yetter A, Sun XJ, White MF: The type 1 interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate-2. J Biol Chem 1996, 271:278-282.
27. Sung CK, Sanchez-Margalet V, Goldfine I: Role of p85 subunit of phosphatidylinositol-3-kinase as an adaptor molecule linking the insulin receptor, p62, and GTPase-activating protein. J Biol Chem 1994, 269:12503-12507.
28. Nolte RT, Eck MJ, Schlessinger J, Shoelson SE, Harrison SC: Crystal structure of the PI-3 kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nature Struct Biol 1996, 3:364-374.
29. Pons S, Asano T, Glasheen E, Miralpeix M, Weiland A, Zhang Y, Myers MGJ, Sun X, White MF: The structure and function of p55PIK reveals a new regulatory subunit for the phosphatidylinositol-3 kinase. Mol Cell Biol 1995, 15:4453-4465.
30. Proud CG: p70 S6 kinase: an enigma with variations. Trends Biochem Sci 1996, 21:181-185. A brief and critical review of the still somewhat mysterious pathway downstream of PI-3 kinase.
31. SeK.
32. SeK.
33. SeK.
34. Yamauchi K, Milarski KL, Saltiel AR, Pessin JE: Protein-tyrosine phosphatase SHPTP2 is a required positive effector for insulin downstream signaling. Proc Natl Acad Sci U S A 1995, 92:664-668. First demonstration of a phosphatase being positively involved in insulin action.
35. Eck MJ, Pluskey S, Trüb T, Harrison SC, Shoelson SE: Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature 1996, 379:277-280.
36. Lin TA, Kong X, Haystead TAJ, Pause A, Belsham G, Sonenberg N, Lawrence JCJ: PHAS-1 as a link between mitogen-activated protein kinase and translation initiation. Nature 1994, 266:653-656.
37. Pillay TS, Sasaoka T, Olefsky J: Insulin stimulates the tyrosine dephosphorylation of pp125 focal adhesion kinase. J Biol Chem 1995, 270:991-994. An unusual example of insulin activation of a downstream target by dephosphorylation.
38. Schaller MD, Parsons JT: pp125 FAK-dependent tyrosine phosphorylation of paxillin creates a high affinity binding site for Crk. Mol Cell Biol 1995, 15:2635-2645.
39. Knight JB, Yamauchi K, Pessin J: Divergent insulin and platelet-derived growth factor regulation of focal adhesion kinase (pp125 Fak) tyrosine phosphorylation, and rearrangement of actin stress fibers. J Biol Chem 1995, 270:10199-10203.
40. Polte TR, Hanks SK: Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130 cas. Proc Natl Acad Sci U S A 1995, 92:10678-10682.
41. Biener Y, Feinstein R, Mayak M, Kaburagi Y, Kadowaki T, Zick Y: Annexin II: a novel element In insulin signal transduction: role of annexin II phosphorylation in insulin receptor internalization. Exp Clin Endocrinol Diabetes 1996, 104(suppl 2):57-58.
42. Ribon V, Mastick CC, Saltiel AR: C-cbl undergoes tyrosine phosphorylation and interacts with specific SH2 domains in response to insulin. Diabetes 1996, 45(suppl 2): 107.
43. Mastick CC, Brady MJ, Saltiel AR: Insulin specifically stimulates the tyrosine phosphorylatlon of caveolin in 3T3-L1 adipocytes. Diabetes 1995, 44(suppl 1):50a.
44. Yeh TC, Ogawa W, Danielsen AG, Roth RA: Isolation of a cDNA encoding a previously uncharacterized substrate of the insulin receptor family. Tenth International Congress of Endocrinology Program and Abstracts, vol 1. San Francisco, 1996; abstract p1-31.
45. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart TA, Reaven GM, Goldfine ID: Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995, 373:448-451. An intriguing novel putative biochemical link between the insulin receptor and insulin resistance in non-insulin-dependent diabetes mellitus.
46. Liu F, Roth RA: Grb-IR: a SH2-domain-containing protein that binds to the insulin receptor and inhibits its function. Proc Natl Acad Sci U S A 1995, 92:10287-10291.
47. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman B: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 1996, 271:665-668. A novel intriguing biochemical link between the insulin signaling pathway and insulin resistance in non-insulin-dependent diabetes mellitus.
48. Kanety H, Feinstein R, Papa M, Hemi R, Karasik A: Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1. Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 1995, 270:23780-23784. A novel intriguing biochemical link between the insulin signaling pathway and insulin resistance in non-insulin-dependent diabetes mellitus.
49. Mothe I, Van Obberghen E: Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action. J Biol Chem 1996, 271:11222-11227. The demonstration of a direct link between IRS-1 serine phosphorylation and the modulation of its activity by regulating its tyrosine phosphorylation and PI-3 kinase activations.
50. Graves LM, Lawrence JC: Insulin, growth factors, and cAMP. Antagonism in the signal transduction pathways. Trends Endocrinol Metab 1996, 7:43-50.
51. Seedorf K, Shearman M, Ullrich A: Rapid effects of protein kinase C on receptor tyrosine kinase phosphorylation and degradation. J Biol Chem 1995, 270:18953-18960.
52. Pillay TS, Xiao S, Olefsky JM: Glucose-Induced phosphorylation of the Insulin receptor. Functional effects and characterization of phosphorylation sites. J Clin Invest 1996, 97:613-620.
53. Kulas DT, Zhang W-R, Goldstein B, Furlanetto RW, Mooney RA: Insulin receptor signaling is augmented by antisense inhibition of the protein tyrosine phosphatase LAR. J Biol Chem 1995, 270:2435-2438.
54. Møller NPH, Møller KB, Lammers R, Kharitonenkov A, Hoppe E, Wiberg F, Sures I, Ullrich A: Selective down-regulation of the insulin receptor signal by protein-tyrosine phosphatase α and ε. J Biol Chem 1995, 270:23126-23131.
55. Seedorf K, Juhl L, Hansen L, Nielsen L, Mosthaf L: Insulin-induced activation of MAP kinase involves Grb-2, SHPTP2, PI-3 kinase and PLCγ. Exp Clin Endocrinol Diabetes 1996, 104:138-139.
56. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD-098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494. A novel and powerful tool to investigate the role of the Ras-MAP kinase pathway, as wortmannin and LY24009 did for the PI-3 kinase pathway and rapamycin for the P70 S6 kinase pathway. Studies solely based on inhibitors must be taken with some caution, however, because the specificity of inhibitors often broadens with further studies.
57. Azpiazu I, Saltiel AR, De Paoli-Roach AA, Lawrence JC: Regulation of both glycogen synthase and PHAS-1 by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways. J Biol Chem 1996, 271:5033-5039. A classic insulin effect on glycogen synthetase and an important new pathway linking insulin to protein synthesis are found to be independent of MAP kinase.
58. Kasuga M, Yonezawa K, Hara K, Sakaue M, Noguchi T, Matozaki T: Role of IRS-1 associated proteins in Insulin signaling. Tenth International Congress of Endocrinology Program and Abstracts, vol 1. San Francisco 1996; abstract S43-41.
59. Haruta T, Morris A, Rose D, Nelson G, Mueckler M, Olefsky J: Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. J Biol Chem 1995, 270:27991-27994. An elegant use of technology, that of single-cell microinjection of 3T3-L1 adipocytes coupled with immunofluorescent detection of GLUT4 proteins, to demonstrate the importance of PI-3 kinase but not MAP kinase in GLUT4 translocation.
60. Ogawa W, Sakaue H, Takada M, Kuroda S, Kotano K, Ueno H, Kasuga M: Introduction of dominant negative molecules into 3T3L1 adipocytes using adenovirus vector. Exp Clin Endocrinol Diabetes 1996, 104(suppl 2):132.
61. Gnudi L, Frevert EU, Houseknecht KL, Kahn BB: Use of recombinant adenovirus-mediated gene transfer to investigate the effects of dominant negative ras on the activation of PI3 kinase and glucose transport in 3T3L1 adipocytes. Exp Clin Endocrinol Diabetes 1996, 104(suppl2):132-133.
62. Ursa B, Christoffersen CT, Ouwens M, Vlahos C, Tornqvist C, White MF, Naor D, De Meyts P: Mitogenic signalling by insulin in a T-cell lymphoma, the LB cell line, devoid of IGF-1 receptors: evidence for the lack of involvement of the Ras-MAP kinase pathway and for a possibly novel IRS-like molecule. Exp Clin Endocrinol Diabetes 1996, 104(suppl2):52-53.
63. Pierreux CE, Ursø B, Aidant N, De Meyts P, Rousseau GG, Lemaigre FP: Signaling pathway leading to the insulin-induced inhibition of 6-phosphofructokinase/fructose-2,6-bisphosphatase gene transcription. Exp Clin Endocrinol Diabetes 1996, 104(suppl 2): 123.
64. Stephens JM, Pilch PF: The metabolic regulation and vesicular transport of GLUT4, the major insulin-responsive glucose transporter. Endocrine Rev 1995, 16:529-546.
65. Birnbaum MJ, James D: The insulin-regulatable glucose transporter GLUT-4. Curr Opin Endocrinol Diabetes 1995, 2:383-391.
66. Kamohara S, Hayashi H, Todaka M, Kanai F, Ishii K, ImanakaT, Escobedo JA, Williams LT, Ebina Y: Platelet-derived growth factor triggers translocation of the insulin-regulatable glucose transporter (type 4) predominantly through phosphatidylinositol 3-kinase binding sites on the receptor. Proc Natl Acad Sci U S A 1995, 92:1077-1081.
67. Isakoff SJ, Taha C, Rose E, Marcusohn J, Klip A, Skolnik EY: The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Proc Natl Acad Sci U S A 1995, 92:10427-10251.
68. Wiese RJ, Corley-Mastick C, Lazar DF, Saltiel AR: Activation of mitogen-activated protein kinase and phosphatidylinostol 3-kinase is not sufficient for the hormonal stimulation of glucose uptake, lipogenasis, or glycogen synthesis in 3T3-L1 adipocytes. J Biol Chem 1995, 270:3442-3446.
69. Navé BT, Haigh RJ, Hayward AC, Siddle K, Sheperd PR: Compartment-specific regulation of phosphoinositide 3-kinase by platelet-derived growth factor and insulin in 3T3-L1 adipocytes. Biochem J 1996, 318:55-60. An important demonstration of the importance of subcellular compartmentalization of signaling components on signal specificity.
70. Ricort J-M, Tanti J-F, Van Obberghen E, Le Marchand-Brustel Y: Different effects of insulin and platelet-derived-growth-factor on phosphatidylinositol 3-kinase at the subcellular level in 3T3-L1 adipocytes. Eur J Biochem 1996, in press. An important demonstration of the importance of subcellular compartmentalization of signaling components on signal specificity.
71. Argetsinger LS, Hsu GW, Myers GW, Billestrup N, White MF, Carter-Su C: Growth hormone, interferon γ, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate 1. J Biol Chem 1995, 270:14685-14692.
72. Ridderstrale M, Degerman E, Tornqvist H: Growth hormone stimulates the tyrosine phosphorylation of the insulin receptor substrate-1 and its association with phosphatidylinositol 3-kinase in primary adipocytes. J Biol Chem 1995, 270:3471-3474.
73. Giorgetti-Peraldi S, Peyrade F, Baron V, Van Obberghen E: Involvement of Janus kinases in the insulin signaling pathway. Eur J Biochem 1995, 234:656-660.
74. van Biesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ: Receptor tyrosine kinase-mediated and G β/γ-mediated MAP kinase activation by a common signaling pathway. Nature 1995, 376:781-784.
75. Lefkowitz RJ: G-protein-coupled receptors and receptor kinases: from molecular biology to potential therapeutic applications. Nature Biotechnol 1996, 14:283-286.
76. iα2. Nature 1996, 379:840-844.
77. De Meyts P, Christoffersen CT, Ursø B, Wallach B, Grønskov K, Yakushiji F, Shymko RM: Role of the time factor in signaling specificity. Application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases. Metabolism 1995, 44(suppl4):1-11.
78. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG: Sustained signaling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996, 315:271-279. Analogues of insulin with a disproportionately high mitogenic potency are shown to have an increased residence time on the insulin receptor compared with analogues without enhanced mitogenic potency. This is shown to induce sustained insulin receptor tyrosine kinase activation and Shc phosphorylation, but not sustained IRS-1 phosphorylation. A landmark study of the emerging concept of the importance of the time factor in selecting signaling pathways.
79. Kublaoui B, Lee J, Pilch PF: Dynamics of signaling during insulin-stimulated endocytosis of its receptor in adipocytes. J Biol Chem 1995, 270:59-65. An emerging fundamental concept: the importance of cell trafficking dynamics in signaling specificity.
80. Bevan AP, Drake P, Bergeron JJM, Posner BI: Intracellular signal transauction: the role of endosomes. Trends Endocrinal Metab 1996, 7:13-21. A provocative review that underlines the importance of cell dynamics.
81. Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J, Bucchini D: Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996, 15:1542-1547. The knockout of the insulin receptor gene raises a fascinating question-why did human patients with the same gene deletion have such a different phenotype?
82. Accili D, Drago J, Lee EJ, Johnson MD, Cool M, Salvatore P, Asico LD, Jose PA, Taylor SI, Westphal H: Early neonatal death In mice homozygous for a null allele of the insulin receptor gene. Nature Genet 1996, 12:106-109. The knockout of the insulin receptor gene raises a fascinating question-why did human patients with the same gene deletion have such a different phenotype?
83. Efstratiadis A: Genetics of growth: developmental roles of IGF and insulin receptors. Exp Clin Endocrinol Diabetes 1996, 104(suppl 2):4-6.
84. Katz EB, Stenbit A, E., Hatton K, DePinho R, Charron MJ: Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995, 377:151-155. One of the year's big surprises: no diabetes in the homozygous GLUT4 knockout (as is the case for the IRS-1 knockouts). Is this a validation of the diabeto-genes concept? (See De Meyts [Adv Exp Biol Med 1993, 334:89-100].)
85. Katz EB, Stenbit A, E., Hatton K, DePinho R, Charron MJ: Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995, 377:151-155. One of the year's big surprises: no diabetes in the homozygous GLUT4 knockout (as is the case for the IRS-1 knockouts). Is this a validation of the diabeto-genes concept? (See De Meyts [Adv Exp Biol Med 1993, 334:89-100].)
86. De Meyts P: The diabetogenes concept of NIDDM. Adv Exp Biol Med 1993, 334:89-100.
87. Bruening JC, Winnay J, Bonner-Weir S, Accili D, Kahn CR: Creating polygenic models of insulin resistance and diabetes mellitus. J Invest Med 1996, 44:A258.